BEVERLY HILLS, CA , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, today announced that it has retained IND 2 Results, LLC, (I2R) Atlanta Georgia, to serve as its Contract Research Organization (CRO).
I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin’s Lymphoma (HL). Subsequently, the Company intends to have I2R assist in preparing the protocol for submission to the Food and Drug Administration (FDA).
In addition, I2R is assisting the Company in amending the Acute Myelocytic Leukemia (AML) protocol in preparation for the Submission Package to a major U.S. clinical site soon-to-be-named, and I2R will also prepare submission packages for the clinical site’s Institutional Review Board (IRB). In cooperation with the clinical site, and subject to the receipt of adequate additional funding, Rich Pharmaceuticals plans to conduct a study for the treatment of AML in refractory patients in Phase I/II trial. AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population ages.
“I2R has a strong track record of success in conducting complicated clinical trials. Its multi-disciplinary team of experienced clinical trial professionals will work with Rich Pharmaceuticals as we move forward with our innovative treatment for lymphoma and leukemia,” said Ben Chang, Rich Pharmaceuticals CEO. “We believe that getting a talented CRO team on board is an important step for our future.”
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Learn more at www.richpharmaceuticals.com.
Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, including the business and product development plans contained in this news release, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.